Celgene

This just may be a great time to begin accumulating shares of Celgene Corporation. This company has been in an overall uptrend for the last fifteen years and technicians are seeing something that may be signaling that the shares are about to move higher. Shares rose from 2003 thru 2007 before hitting resistance near $40 per share. At that point the stock moved sideways for the next six years as it struggled to break above that $40 resistance.

In 2013 the stock broke out again and moved higher. As it approached $130 per share the stock once again hit resistance and pulled back. It has now been moving sideways for two years and is approaching a technical uptrend line (see below). You can almost see a pennant forming forcing the shares more and more toward $130. 

From a purely technical view, as these shares move higher thru the $130 per share level, the shares could see a significant move higher. Shares could easily double within a year of the breakout and triple over a couple of years.

And that would be an incredible move! 

Celgene Corporation Monthly Chart

​Celgene Corporation discovers, develops, and commercializes therapies to treat cancer and inflammatory diseases worldwide. It markets REVLIMID, an oral immunomodulatory drug for multiple myeloma, myelodysplastic syndromes (MDS), and mantle cell lymphoma; ABRAXANE, a solvent-free chemotherapy product to treat breast, non-small cell lung, pancreatic, and gastric cancers; POMALYST/IMNOVID to treat multiple myeloma; and OTEZLA, a small-molecule inhibitor of phosphodiesterase 4 for psoriatic arthritis, psoriasis, ankylosing spondylitis, Behcet's disease, atopic dermatitis, and ulcerative colitis. The company's products also include VIDAZA, a pyrimidine nucleoside analog to treat intermediate-2 and high-risk MDS, and chronic myelomonocytic leukemia, as well as acute myeloid leukemia (AML); THALOMID for the patients with multiple myeloma and erythema nodosum leprosum; ISTODAX to treat cutaneous and peripheral T-cell lymphoma; and FOCALIN, FOCALIN XR, and RITALIN products. Its clinical stage products include OTEZLA for the treatment of various immune-inflammatory diseases; sotatercept for the treatment of renal anemia, beta-thalassemia and MDS; luspatercept for beta-thalassemia and MDS; CC-486 to treat MDS, AML, and solid tumors; CC-122 and CC-220 to treat hematological and solid tumor cancers, and inflammation and immunology diseases; PDA-002 for the treat diabetic foot ulcers and peripheral neuropathy; and PNK-007 for hematological malignancies treatment. The company has collaborative agreements with Novartis Pharma AG; Acceleron Pharma; Agios Pharmaceuticals, Inc.; Epizyme Inc.; Sutro Biopharma, Inc.; bluebird bio, Inc.; FORMA Therapeutics Holdings, LLC; Acetylon Pharmaceuticals, Inc.; OncoMed Pharmaceuticals, Inc.; NantBioScience, Inc.; AstraZeneca PLC; Lycera Corp.; Juno Therapeutics, Inc.; TriNetX, Inc.; Triphase Accelerator Corporation; Nurix Inc.; Abbott; Sage Bionetworks; and PharmAkea Inc. The company was founded in 1980 and is headquartered in Summit, New Jersey.
(Summary) (Company) (Chart)

11 February 2016
Price $115.61
1yr Target $141.22
Analysts 23
Dividend ---
Payout Ratio ---

1yr Cap Gain 22.15%
Yield ---
1yr Tot Return 22.15%

P/E 46.50
PEG 2.07
Beta 1.79

EPS (ttm) $2.49
EPS next yr $8.71
Forward P/E 13.28
EPS next 5yr 22.44%
1yr Price Support $195.45

Market Cap $89.54 Bil
Revenues $11.23 Bil
Earnings $2.00 Bil
Profit Margin 17.80%

Quick Ratio ---
Current Ratio ---
Debt/Equity ---

1yr RevGR 21.31%
3yr RevGR 19.81%
5yr RevGR 18.32%

1yr EarnGR 28.35%
3yr EarnGR 13.86%
5yr EarnGR 11.80%

1yr DivGR ---
3yr DivGR ---
5yr DivGR ---

ROA ---
ROE ---